Search Results
Results found for "Cancer Research UK"
Posts (322)
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring immunotherapy benefits to new cancer types. Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent £388 million on cancer research last fiscal year. Much of that funding is distributed to support third party research, but the group also does its own
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials "HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 22 July 2022 – Sosei Research UK, the world’s largest private funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial."
- Fluorescence Polarization in GPCR Research
How Fluorescence Polarization Assays Work: Principles and Applications in GPCR Research FP assays work Ligands Looking ahead, fluorescence polarization technology is expected to expand its role in GPCR research
Other Pages (298)
- Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer
Rottapel is a Senior Scientist at the Princess Margaret Cancer Centre where he holds the Amgen Chair for Cancer Research. University, the NIH and UCLA, he pursued his postdoctoral studies with Allan Bernstein at the Lunenfeld Research Rottapel’s research interests lies in the elucidation of signal transduction pathways in cancer, immune Robert Rottapel on the web The Rottapel Lab Ontario Institute for Cancer Research University of Toronto
- G Proteins and GPCRs in Cancer: Novel Precision Targeted and Immunotherapies
Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule G Proteins and GPCRs in Cancer Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer His research team has pioneered the study of G proteins and G protein coupled receptors (GPCRs) in human Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Pubmed LinkedIn Twitter UCSD Moores Cancer Center Dr.
- Dr. Michael Feigin | Dr. GPCR Ecosystem
Research, 2014) and GPCRs (Feigin, et al., PNAS, 2014) in breast cancer pathogenesis, using mouse models They also discussed his research on cell polarity and its role in cancer progression, his work on G-protein Mike's Research on Cell Polarity and GPCRs in Cancer Mike shared his research on cell polarity and its GPCR Targeted Drugs and Gene Regulation in Cancer Cells Mike presented research on the effect of GPCR-targeted GPCRs and Cancer Immune Modulation Yamina and Mike had a discussion about their research on GPCRs, specifically





